Domestic pharmaceutical companies that invested more than 1 billion yuan in research and development in the first half of the year have a variety of potential first-in-class


2022-09-26: [Chinese Article Link] First in Class is the first new mechanism drug that can treat a disease. Since the release on 19 November 2021 of the CREE Guidelines for Clinical Research and Development on Anti-Cancer Medicines with Clinical Values, a new policy to combat “pseudo-innovation”, domestic pharmaceutical companies have


Note: This is a machine translated version of the Chinese news media article. A mature and nuanced reading is suggested.

Trending in China
What China Reads


Domestic pharmaceutical companies that invested more than 1 billion yuan in research and development in the first half of the year have a variety of potential first-in-class


2022-09-26: [Article Link] First in Class is the first new mechanism drug that can treat a disease. Since the release on 19 November 2021 of the CREE Guidelines for Clinical Research and Development on Anti-Cancer Medicines with Clinical Values, a new policy to combat “pseudo-innovation”, domestic pharmaceutical companies have

Note: This is a translated version of the Chinese news media article. A mature and nuanced reading is suggested.